Biohaven’s New Epilepsy Treatment Shows Promising Results in Phase 1 Studies
Biohaven, has unveiled optimistic data from its recent Phase 1 EEG biomarker study of BHV-7000, a novel epilepsy treatment. The research centered on assessing qualitative EEG changes post-administration of BHV-7000 in different doses, providing an insight into its potential effects.
